CGPHF (Grand Pharmaceutical Group) Total Operating Expense: $652.10 Mil (TTM As of Dec. 2025)


What is Grand Pharmaceutical Group Total Operating Expense?

Grand Pharmaceutical Group CGPHF 86 Total Operating Expense is $652.10 Mil as of Dec. 2025. GuruFocus rates CGPHF with a GF Score™ of 86/100. The stock has 6 warning signs investors should review.

Grand Pharmaceutical Group's Total Operating Expense for the six months ended in Dec. 2025 was $319.81 Mil. Grand Pharmaceutical Group's Total Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 was $652.10 Mil.

Grand Pharmaceutical Group Total Operating Expense Related Terms

Grand Pharmaceutical Group Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Grand Pharmaceutical Group's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Grand Pharmaceutical Group Total Operating Expense Chart

Grand Pharmaceutical Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 414.50 419.80 473.86 587.42 655.00

Grand Pharmaceutical Group Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 175.06 284.02 302.07 332.29 319.81

Grand Pharmaceutical Group Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $652.10 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of $652.10 Mil mean?
Grand Pharmaceutical Group (CGPHF) has a Total Operating Expense of $652.10 Mil as of Dec. 2025. Total operating expense is the primary recurring expense associated with central operations. View historical data on Grand Pharmaceutical Group and its competitors.
Is Grand Pharmaceutical Group's Total Operating Expense too high?
Grand Pharmaceutical Group's current Total Operating Expense is $652.10 Mil. Overall, Grand Pharmaceutical Group has a GF Score™ of 86/100, reflecting its overall financial health beyond just this single metric.
How does Grand Pharmaceutical Group's Total Operating Expense compare to ZTS and UTHR?
Grand Pharmaceutical Group's Total Operating Expense of $652.10 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Drug Manufacturers company?
A good Total Operating Expense depends on the Drug Manufacturers industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Grand Pharmaceutical Group and its competitors. Grand Pharmaceutical Group's current Total Operating Expense is $652.10 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Grand Pharmaceutical Group stock overvalued right now?
Grand Pharmaceutical Group (CGPHF) has a current Total Operating Expense of $652.10 Mil. The current Total Operating Expense is $652.10 Mil. Grand Pharmaceutical Group's overall GF Score™ is 86/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Grand Pharmaceutical Group (CGPHF), the current Total Operating Expense is $652.10 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Grand Pharmaceutical Group Business Description

Other Exchanges 00512:Hong KongMX6A:Germany
Address 99 Queen\'s Road Central, Units 3302, 33rd Floor, The Center, Hong Kong, HKG
Grand Pharmaceutical Group Ltd are principally engaged in the manufacture and sales of pharmaceutical technology products, manufacture and sales of bio-technology products as well as manufacture and sales of nuclear medicine anti-tumor diagnosis and treatment and cerebro-cardiovascular precision interventional diagnosis and treatment technology products, in the People's Republic of China. The operation of the group constitutes one single reportable segment. The company has presence in The PRC, America, Europe, Asia other than the PRC and Others. The majority of revenue comes from the PRC. Its brands are breathe, biology, Cardiovascular emergency care, Cardiovascular intervention, ENT, tumor.